- Participants are being sought for a study to be conducted at six U.S. sites that will help researchers identify and characterize biomarkers (biological indicators) in ALS.
- Participants will be required to donate samples of blood and cerebrospinal fluid.
- Accurate biomarkers are needed to measure the onset or progression of ALS, and to assess the effectiveness of experimental ALS therapeutics.
The Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) is actively seeking participants for a study designed to identify and validate biomarkers in amyotrophic lateral sclerosis (ALS).
A biomarker is a biological indicator that can be used to measure the onset or progression of a disease, how a disease is reacting to a treatment or how a drug is behaving in the body.
The purpose of the study is to collect biological samples from a number of people with ALS, and bank them for current and future usage in ALS research.
Through analysis and comparison of the samples, the researchers hope to learn more about the underlying causes of ALS and find unique biomarkers for the disease.
About the study
Study investigators expect to enroll approximately 250 participants for the study, which is set to take place at six sites: Phoenix, Ariz.; Jacksonville, Fla.; Atlanta; Charlestown, Mass.; Worcester, Mass.; and Pittsburgh.
Those taking part in the study will be required to submit blood and cerebrospinal fluid (CSF) samples.
Participants must be age 18 or older; have a diagnosis of suspected, possible, probable or definite ALS according to El Escorial Criteria; and meet other study requirements.
To participate in the biomarkers trial
More details about the study can be found at:
To participate in the study, contact the site nearest you or Sarah Titus at the Massachusetts General Hospital Coordination Center: (617) 726-1398 or email@example.com.